KZIA Kazia Therapeutics Ltd

STAMFORD, Conn. and SYDNEY, Australia, Jan. 17 /PRNewswire-FirstCall/ -- Pharmaceutical company, Novogen Limited, announced today that its U.S. subsidiary, Glycotex Inc., has appointed Dr Reinhard Koenig as chief executive officer and president. Glycotex Inc. is a clinical stage biopharmaceutical company focused on discovering and developing a new class of drugs for human wound healing and tissue repair. Dr. Koenig will also be a director of the company. Other directors include Mr. Christopher Naughton (chairman), Mr. David Seaton (chief financial officer, director and secretary), Ms. Katherine Szem (chair of the Audit Committee), Mr. William Rueckert and Mr. Philip Johnston. Following the appointment of Dr. Koenig, Glycotex will be headquartered in San Francisco. Dr. Koenig has more than 18 years of pharmaceutical experience in small and emerging biotech and pharmaceutical companies as well as in multinational companies. His most recent position has been Vice President, Clinical and Product Development at Questcor Pharmaceuticals Inc., a specialty pharmaceutical company. Previous appointments include Senior Vice president, Medical and Regulatory Affairs at Imcor Pharmaceuticals Inc., previously known as Photogen Technologies Inc., Chief Medical Officer at Collagen Aesthetics, Inc., a manufacturer of tissue augmentation products, Director, Medical Information and Drug Experience at Genentech, Inc., a manufacturer of biotechnology products, and Director, Medical Affairs at Boehringer Mannheim Therapeutics, a manufacturer of pharmaceuticals. He received his medical degree at Medical School at Philipps University in Marburg, Germany. He also received his doctorate in toxicology and pharmacology from Philipps University, Marburg. Novogen (NASDAQ:NVGN)(ASX:NRT) is a world leader in the research and development of drugs derived from its phenolic technology platform. Novogen manages its international research and development programs using the expertise and clinical research capabilities of universities and hospitals in the U.S., Australia and other key international locations. Novogen's U.S. listed subsidiary Marshall Edwards Inc. (NASDAQ:MSHL) is developing the oncology compound phenoxodiol. More information on the Novogen group of companies can be found at http://www.novogen.com/ and http://www.marshalledwardsinc.com/. Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third arty patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements. First Call Analyst: FCMN Contact: DATASOURCE: Novogen Limited CONTACT: Mr. Christopher Naughton, Managing Director of Novogen Limited, +011 (2) 9878 0088; or David Sheon, +1-202-518-6321, for Novogen Limited Web site: http://www.novogen.com/ http://www.marshalledwardsinc.com/

Copyright